Dentists in Russell Springs, KY Accepting Medicare
3 Dentists found. Showing 1 - 3
 Dr. Henry Stephenson Smith, DMD Dentist Medicare: Not Enrolled in Medicare Practice Location: 519 Main Street, Russell Springs, KY 42642 Phone: 270-866-3560 Fax: 270-866-3560 |
Dr. Robert Brian Grippe, DMD Dentist Medicare: Medicare Enrolled Practice Location: 458 N Main St, Russell Springs, KY 42642 Phone: 270-866-7222 |
 Dr. Shana G. Hughes, D.M.D. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 24 Caden Way Ste. 3, Russell Springs, KY 42642 Phone: 270-866-4101 Fax: 270-866-4133 |
News Archive
Georgia physicians file lawsuit alleging that HMOs have not paid Medicaid claims
Three private HMOs contracting with Georgia to oversee care for Medicaid beneficiaries have not paid providers for millions of dollars in outstanding claims, according to a lawsuit filed Tuesday in Fulton County, Ga., Superior Court, the Atlanta Journal-Constitution reports.
WRAIR to test Kane Biotech's DispersinB biofilm technology against pathogens in combat trauma wounds
Kane Biotech Inc. (TSX VENTURE:KNE), a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that the Company has entered into a Cooperative Research and Development Agreement for Material Transfer (CRADA-MT) with the Walter Reed Army Institute of Research (WRAIR) in Silver Springs, Maryland.
Trial date set for patent litigation in the U.S. District Court for the District of Delaware
Cubist Pharmaceuticals, Inc. today announced that a trial date has been set for patent litigation in the U.S. District Court for the District of Delaware against Teva Parenteral Medicines, Inc. (TPM), Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. alleging infringement of Cubist's US Patent Nos. 6,468,967 and 6,852,689, which expire on September 24, 2019, and US Patent No. RE39,071, which expires on June 15, 2016.
Cholesterol-lowering drugs linked to higher risk for developing type 2 diabetes
Individuals who take cholesterol-lowering statins may be at higher risk for developing high blood sugar levels, insulin resistance, and eventually type 2 diabetes, according to an analysis published in the British Journal of Clinical Pharmacology.
Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC
Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).
› Verified 2 days ago
Pharmacists
Counselors
Clinical Social Workers
Dentists
Psychologists